References
1. Parker SL, Tong T, Colden S, Wingo PA: Cancer Statistics, 1996. CA: A Cancer Journal for Clinicians: 46:(1)5-27, 1996.
2. Cohen SM and Johansson: Epidemiology and etiology of bladder cancer. Urologic Clinics of North America 19(3):421-428, 1992.
3. Badalament RA, Kimmel M, Gay H, Cibas ES, Whitmore WF, Herr HW, Fair WR and Melamed MR: The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer, 59(12):2078-2085, 1987.
4. Wheeles LL, Badalament RA, deVere White RW, Fradet Y, and Tribukait B: Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry, 14:478-481, 1993.
5. Sarosdy M, deVere White R, Soloway M, Scheinfeld J, Hudson M, Schellhemmer P, Jarowenkow M, Adams G, Ellis W, Messing E, Johnson R, Patel J, Schervish E, Chodak G, Lamm D, Henderson M, Blumstein B: Result of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol, 153(4):75A, 1995.
6. Badalament RA, Sethi PS, Bennett WF, and Bova JG: Imaging of Transitional Cell Carcinomas of Urinary Tract. In Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS. Editors, Philadelphia, Willians & Wilkins, 1996, pages 371-387.
7. Badalament RA, Ortolano V, and Burgers JK: Recurrent or aggressive bladder cancer: Indications for adjuvant intravesical therapy. Urologic Clinics North America, 19(3):485-498, 1992.
8. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urologic Clinics North America, 19(3):573-580, 1992.
9. Wientjes MG, Badalament RA, and Au JL-S: Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical Mitomycin C therapy for superficial bladder cancer. Cancer Chemotherapy and Therapeutics, 32:255-262, 1993.
10. Perry JJ, Hyman BM: Management of disseminated disease in the patient with bladder cancer. Urologic Clinics North America, 21(4):661-672, 1994.
11. Wesson MF: Radiation therapy in regionally advanced bladder Cancer. Urologic Clinics of North America, 19(4):725-734, 1992.
12. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AG, Efrid JT: Selective bladder preservation by combination treatment of invasive bladder cancer. NEJM, 329:1377-1382, 1993.
13. Herr HW, Scher HI: Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12:975-980, 1994.
14. McDougal WS: Use of intestinal segments in the urinary tract: Basic principles. In Campbell's Urology 6th Edition. Walsh PC, Retik AB, Stamey TA, Vaughn ED, Editors, Philadelphia, WB Saunders, 1992, pages 2595-2629.
15. Scher HI: Systemic chemotherapy in egionally advanced bladder cancer.Theoretical considerations. Urologic Clinics of North America, 19:747-760, 1992.
16. Badalament RA: Transitional Cell Carcinoma: A common sense approach. J Urol, 153(1):61-62, 1995.
17. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994.
18. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ: Phase
II trial of vinblastine, ifosfamide and gallium combination chemotherapy
in metastatic urothelial carcinoma. J Clin Oncol 12:2271-2276, 1994.
Cancer News on the Net wishes to thank Dr Badalament for contributing this fine article to our service!!!
To access any part of this article just click over the name of the section